Evidence indicates that following the 2012 USPSTF recommendation against routine PSA screening, the incidence of advanced and newly metastatic prostate cancer has risen annually, suggesting that reduced early detection may have contributed to the slower decline in AAMRs [15–20]. This evidence concerns the gene KLK3 and Familial prostate cancer.